Filing summary
Issuer mismatch: The request identifies Oruka Therapeutics, Inc., but the supplied Form 10-K is for ARCA biopharma, Inc. (Nasdaq: ABIO). This summary reflects the filing provided, not an Oruka filing.
Business context and reporting period
Annual report for the fiscal year ended December 31, 2021, filed March 14, 2022. ARCA was a clinical-stage biopharmaceutical company with no approved products or product revenue. Its lead programs were rNAPc2 (AB201), under study for hospitalized COVID-19 patients at risk of coagulation complications, and Gencaro, being developed for atrial fibrillation in selected heart-failure patients.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $13.8 million | $5.0 million |
| General and administrative expense | $5.5 million | $4.8 million |
| Operating loss | $19.3 million | $9.8 million |
| Net loss | $19.3 million | $9.7 million |
| Net cash used in operating activities | $18.8 million | $7.7 million |
| Cash and cash equivalents at year-end | $53.4 million | $49.1 million |
| Total liabilities | $3.9 million | $3.9 million |
| Debt outstanding | None | None |
Margins are not meaningful given the absence of product revenue. Stockholders’ equity was $51.0 million at year-end 2021. Financing activities provided $23.1 million in 2021, primarily from equity issuance; the company issued 4.86 million shares during the year.
Material changes versus the prior period
- R&D expense rose $8.8 million, principally reflecting the rNAPc2 trial and related manufacturing. Management expected 2022 R&D expense to be broadly consistent with 2021.
- Net loss increased from $9.7 million to $19.3 million, and operating cash use rose from $7.7 million to $18.8 million.
- Year-end cash increased by $4.3 million because equity proceeds more than offset operating and investing cash outflows.
- Common shares outstanding increased from 9.55 million to 14.41 million, reflecting equity financing and resulting dilution.
Outlook, risks and unusual items
- Management estimated existing cash would fund operations through mid-2023, but said a Phase 3 trial for either rNAPc2 or Gencaro would likely require additional financing. It was pursuing partnering and other strategic transactions; failure to obtain funding could force program reductions or cessation of operations.
- Enrollment in the approximately 160-patient ASPEN-COVID-19 Phase 2b trial was completed in Q4 2021. An interim review by the data monitoring committee recommended completing the study without design changes. At filing, management expected topline results in the last week of March 2022; results are not included in this 10-K.
- Gencaro’s planned Phase 3 PRECISION-AF trial was on hold, pending additional financing and improvement in pandemic conditions sufficient to recruit patients. The FDA Special Protocol Assessment does not guarantee trial success or approval.
- ARCA’s financial statements were prepared on a going-concern basis. The filing highlights uncertainty around future financing, despite the stated cash runway estimate.
- A July 2021 patent assignment for rNAPc2 provides exclusive worldwide rights described in the filing, with potential milestone payments totaling approximately €1.6 million and low-single-digit royalties if the product is approved and commercialized.
- KPMG issued an unmodified audit opinion. Its critical audit matter concerned audit evidence for accrued, unbilled R&D costs. The auditor was not engaged to opine on internal-control effectiveness; management reported controls were effective at year-end.
Investor facts to verify
- Confirm the intended issuer: the supplied filing is ARCA biopharma’s, not Oruka Therapeutics’.
- Check subsequent disclosures for ASPEN-COVID-19 results and any FDA feedback or further rNAPc2 development plans.
- Verify cash runway against actual cash burn, financing activity, and any planned Phase 3 spending.
- Review the terms and availability of further equity financing, including dilution and the public-float sales limitation described in the filing.
- Assess Gencaro’s trial status, funding prospects, and the regulatory and commercial requirements for its genetic diagnostic test.